Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Codexis Sets Up Two Pharma Deals
by Ann M. Thayer
August 17, 2015
| A version of this story appeared in
Volume 93, Issue 32
Codexis has licensed its enzyme engineering technology to Merck & Co., a collaborator of eight years. In return, Codexis will get $5 million up front and up to $13 million over 15 to 24 months as it transfers the technology to a Merck site. If Merck uses enzymes developed with the technology to produce drug ingredients, Codexis can receive up to $15 million per product. In July 2014, Codexis licensed its technology to GlaxoSmithKline for $25 million. Separately, for $1 million up front and R&D payments, Codexis will develop an enzyme for an undisclosed biotherapeutic firm to use in preclinical development.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X